Introduction
============

The Fontan procedure is used to separate the systemic and pulmonary circulations in patients with various forms of functionally univentricular hearts. In the Fontan circulation, systemic venous return is sent to the pulmonary arteries without passage through a ventricle. The Fontan procedure can result in various late complications, including central venous hypertension, diminished oxygen delivery, reduced cardiac output, venous thrombosis, and arrhythmia ([@B1],[@B2]). These complications caused by central venous hypertension lead to parenchymal injury, fibrosis, and cirrhosis of the liver ([@B2],[@B3]). Cardiac cirrhosis is a serious late complication of congenital heart disease and can cause hepatocellular carcinoma (HCC) ([@B4],[@B5]). However, the prevalence and risk factors of cirrhotic changes and HCCs have not been clearly identified. Furthermore, non-invasive diagnostic tools for hepatic fibrosis and the management of HCC in patients after undergoing the Fontan procedure have not yet been clearly established.

We herein report a case of HCC with cardiac cirrhosis treated with surgical resection.

Case Report
===========

A 29-year-old woman with a history of a univentricular heart had undergone a Fontan operation 10 years of age. She also had situs inversus. She was followed-up at the department of pediatric cardiology in our hospital, and regularly underwent blood examinations without alpha-fetoprotein (AFP) at 2- or 3-month intervals. The results showed that the transaminase level was within the normal range. On a routine follow-up day, she experienced slight abdominal discomfort and received abdominal ultrasonography (US). She had an incidental finding of liver masses and was referred to our department.

B-mode conventional US showed a 15 mm hypoechoic mass in liver segment 4 (S4) ([Fig. 1a](#g001){ref-type="fig"}), and an 18 mm hyperechoic mass in liver segment 2 (S2) ([Fig. 2a](#g002){ref-type="fig"}). Furthermore, the liver parenchyma had a coarsened appearance consistent with cirrhosis, and ascites and splenomegaly were observed ([Fig. 1b and c](#g001){ref-type="fig"}).

![Ultrasonography ﬁndings (arrows). B-mode conventional ultrasonography showed a 15 mm hypoechoic mass in liver segment 4 (S4) (a), the liver parenchyma had a coarsened appearance consistent with cirrhosis, and ascites and splenomegaly were observed (b, c).CEUS using Sonazoid showed a homogeneously enhanced mass in the arterial dominant phase (d), a hypoechoic mass relative to the adjacent liver parenchyma during the portal dominant phase (e), and a contrast defect with a clear border in the postvascular phase (f).](1349-7235-55-3265-g001){#g001}

![B-mode conventional ultrasonography showed an 18 mm hyperechoic mass in liver segment 2 (S2) (a); and CEUS showed a homogeneously enhanced mass in the arterial dominant phase (b), isoechoic mass relative to the adjacent liver parenchyma during the portal dominant phase (c), and no defects in the postvascular phase (d).](1349-7235-55-3265-g002){#g002}

We next performed contrast-enhanced US (CEUS) using a bolus injection of 0.015 mL/kg Sonazoid (perfluorobutane; Daiichi-Sankyo, Tokyo, Japan). The mass lesion in S4 was homogeneously enhanced in the arterial dominant phase (from 10 to 30 seconds) ([Fig. 1d](#g001){ref-type="fig"}). The lesion became progressively hypoechoic relative to the adjacent liver parenchyma during the portal dominant phase (from 30 to 120 seconds) ([Fig. 1e](#g001){ref-type="fig"}), and provided a contrast defect with a clear border in the postvascular phase (10 minutes later) ([Fig. 1f](#g001){ref-type="fig"}). The mass lesion in S2 was homogeneously enhanced in the arterial dominant phase ([Fig. 2b](#g002){ref-type="fig"}). The lesion became isoechoic mass relative to the adjacent liver parenchyma during the portal dominant phase ([Fig. 2c](#g002){ref-type="fig"}) and provided no defects in the postvascular phase (10 minutes later) ([Fig. 2d](#g002){ref-type="fig"}).

We subsequently performed magnetic resonance imaging (MRI) with conventional T1-and T2-weighted imaging (WI) before and after contrast media administration, including diffusion imaging. The contrast media used was hepatocyte-specific Primovist \[gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA); Bayer Schering Pharma, Berlin, Germany\]. There was radiographic evidence of liver cirrhosis with portal hypertension, including a nodular surface, a coarse texture, ascites, and splenomegaly on MRI ([Fig. 3a and b](#g003){ref-type="fig"}).

![There was radiographic evidence of liver cirrhosis with portal hypertension, including a nodular surface, a coarse texture, ascites, and splenomegaly on MRI (a, b). Gd-EOB-DTPA MRI showed a 15 mm S4 mass with a moderately low intensity in T1-WI (c), moderately high intensity in T2-WI (d), moderately high intensity in diffusion (e), homogeneous arterial enhancement (b, f), and complete washout in the hepatobiliary phase (g).](1349-7235-55-3265-g003){#g003}

This imaging revealed a mass lesion in S4 with a moderately low intensity in T1-WI ([Fig. 3c](#g003){ref-type="fig"}) and moderately high intensity in T2-WI ([Fig. 3d](#g003){ref-type="fig"}). In diffusion imaging, the lesion showed a moderately high intensity ([Fig. 3e](#g003){ref-type="fig"}). In the postcontrast phases, the lesion revealed homogeneous enhancement in the arterial phase at 20 seconds ([Fig. 3b and f](#g003){ref-type="fig"}), and washout in the portal phase at 70 seconds and interstitial phase at 180 seconds. At 20 minutes (hepatobiliary phase) after the contrast uptake the lesion showed washout ([Fig. 3g](#g003){ref-type="fig"}). According to these findings, a final diagnosis of HCC was made. In addition, MRI imaging revealed a mass lesion in S2 with a moderately high intensity in T1-WI ([Fig. 4b](#g004){ref-type="fig"}) and moderately low intensity in T2-WI ([Fig. 4c](#g004){ref-type="fig"}). In diffusion imaging, the lesion showed a moderately low intensity ([Fig. 4d](#g004){ref-type="fig"}). In the postcontrast phases, the lesion revealed a homogeneous enhancement in the arterial phase ([Fig. 4a and e](#g004){ref-type="fig"}), an isoenhancement relative to the adjacent liver parenchyma in the portal and interstitial phases, and a high intensity in the hepatobiliary phase ([Fig. 4f](#g004){ref-type="fig"}).

![Gd-EOB-DTPA MRI showed an 18 mm S2 mass with a moderately high intensity in T1-WI (b), moderately low intensity in T2-WI (c), moderately low intensity in diffusion (d), homogeneous arterial enhancement (a, e), and high intensity in the hepatobiliary phase (f).](1349-7235-55-3265-g004){#g004}

The laboratory data are given in [Table 1](#t001){ref-type="table"}. Her liver function was well preserved with the Child-Pugh classification A, and her international normalized ratio was low (the patient was on warfarin for atrial arrhythmia). Other lab findings included a high AFP level \[normal less than 40 nanograms/milliliter (ng/mL)\], high Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) (normal less than 10%), low platelet count (normal greater than 150,000/microliter), high hyaluronic acid (normal less than 50 ng/mL), and high type IV collagen 7S (normal less than 6.0 ng/mL). An echocardiogram demonstrated a normal ventricular function and no obstruction in the Fontan circuit. The patient had no other significant medical problems and no other risk factors for cirrhosis, as she expressed negativity for viral and autoimmune markers, no alcoholic consumption, no hepatotoxic drugs (such as amiodarone), and no metabolic factors such as diabetes mellitus, obesity (her body mass index was 17.7), or fatty liver in US. Following the reversal of her warfarin therapy, an ultrasound-guided needle biopsy of the S2 lesion was performed. Histological findings revealed that bridging fibrosis in the liver section, and the parenchymal cells did not display cellular or structural atypia ([Fig. 5](#g005){ref-type="fig"}). The liver mass in S2 was pathologically diagnosed to be a regenerative nodule.

###### 

Results of Blood Tests.

  ---------------------- ---------------- ------------------------ ------------- -------------- -------------
  **Hematology**                          **Blood biochemistry**                 **Serology**   
  WBC                    3.0 ×10^3^ /μL   TP                       7.7 g/dL      HBsAg          (-)
  RBC                    494×10^4^ /μL    Alb                      4.9 g/dL      HBsAb          (-)
  Hb                     9.5 g/dL         ChE                      166 IU/L      HBcAb          (-)
  Hct                    32.7 %           T.Bil                    1.0 mg/dL     HCV-Ab         (-)
  PLT                    12.5×10^4^ /μL   D.Bil                    0.5 mg/dL     ANA            (-)
                                          AST                      23 IU/L       AMA-M2         (-)
                                          ALT                      13 IU/L       IgG            1,267 mg/dL
  **Coagulation test**                    LDH                      226 IU/L      IgA            233 mg/dL
  PT%                    33.1 %           ALP                      163 IU/L      IgM            231 mg/dL
  PT-INR                 1.68             γ-GTP                    47 IU/L       AFP            117.1 ng/mL
                                          ZTT                      8.5 KU        AFP-L3         46.8 %
                                          TTT                      4.6 KU        CEA            0.4 ng/mL
                                          BUN                      19 mg/dL      CA19-9         5.1 ng/mL
                                          Cr                       0.79 mg/dL                   
                                          CRP                      0.010 mg/dL                  
                                          hyaluronic acid          53 ng/mL                     
                                          type IV collagen7S       8.5 ng/mL                    
                                          ICG-R15                  19.9 %                       
  ---------------------- ---------------- ------------------------ ------------- -------------- -------------

WBC: white blood cells, RBC: red blood cells, Hb: hemoglobin, Hct: hematocrit, PLT: platelets, PT: prothrombin time, INR: international normalized ratio, TP: total protein, Alb: albumin, ChE: cholinesterase, T.Bil: total bilirubin, D.Bil: direct bilirubin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, γ-GTP: γ-glutamyltranspeptidase, ZTT: zinc sulfate turbidity test, TTT: thymol turbidity test, BUN: blood urea nitrogen, Cr: creatinine, CRP: C-reactive protein, ICG-R: indocyanine green retention, HBsAg: hepatitis B surface antigen, HBsAb: hepatitis B surface antibody, HBcAb: hepatitis B core antibody, HCV: hepatitis C virus antibody, ANA: antinuclear antibodies, AMA-M2: anti-mitochondrial M2 antibody, AFP: alpha-fetoprotein, AFP-L3: Lens culinaris agglutinin-reactive fraction of AFP, CEA: carcinoembryonic antigen, CA: carbohydrate antigen

![A histological specimen was obtained by an ultrasound-guided needle biopsy of the S2 lesion. Microscopic histological findings revealed bridging fibrosis in the liver section. The parenchymal cells did not display cellular or structural atypia \[Hematoxylin and Eosin staining (a), and silver impregnation (b) with a low-power field\]. The liver mass in S2 was pathologically diagnosed as a regenerative nodule.](1349-7235-55-3265-g005){#g005}

The patient underwent a curative operation, involving partial hepatectomy of S4 in the liver. Macroscopically, sections of the specimen revealed a yellowish-white encapsulated solid tumor measuring 15 mm in size ([Fig. 6a](#g006){ref-type="fig"}).

![A macroscopic appearance of the resected S4 specimen revealed a yellowish-white encapsulated solid tumor measuring 15 mm in size (a). Microscopically, the growth pattern of the S4 liver tumor showed expansive growth with extracapsular invasions \[b, Hematoxylin and Eosin (H&E) staining with a low-power field\]. Tumor cells had an increased nuclear/cytoplasmic ratio, polymorphic, and chromatin-rich nuclei, and the pathological diagnosis was poorly differentiated HCC (c, H&E staining with a high-power field).](1349-7235-55-3265-g006){#g006}

The growth pattern of the liver tumor showed expansive growth with extracapsular invasions ([Fig. 6b](#g006){ref-type="fig"}). The tumor cells had an increased nuclear/cytoplasmic ratio, polymorphic, and chromatin-rich nuclei, and the pathological diagnosis was poorly differentiated HCC ([Fig. 6c](#g006){ref-type="fig"}). The non-cancerous area of the resected specimen revealed that bridging fibrosis was observed without fat deposition, and the patient was diagnosed with liver cirrhosis ([Fig. 7a](#g007){ref-type="fig"}). Fibrosis was observed in both the portal and pericellular areas, the sinusoidal structure was maintained, but no signiﬁcant inflammation was observed ([Fig. 7b and c](#g007){ref-type="fig"}).

![The noncancerous area of the resected specimen revealed bridging fibrosis without fat deposition, and the patient was diagnosed with liver cirrhosis \[silver impregnation (a)\]. Fibrosis was observed in both the portal and pericellular areas, the sinusoidal structure was maintained, and signiﬁcant inﬂammation was not seen \[silver impregnation (b, c) with a high-power field\].](1349-7235-55-3265-g007){#g007}

After discharge from the hospital, the patient was followed-up at 3-month intervals.

At the 1-year follow-up, her AFP level was 2.7 ng/mL, AFP-L3 was less than 0.5%, and the tumor markers remained normal. Furthermore, US and MRI showed no evidence of HCC recurrence.

Discussion
==========

In the present case, there were no known etiological factors such as hepatitis viral infection, alcoholic liver disease, autoimmune liver diseases, autoimmune hepatitis, primary biliary cirrhosis, metabolic liver diseases \[such as non-alcoholic steatohepatitis (NASH)\], or medication with hepatotoxic drugs (such as amiodarone). Moreover, significant hepatic inflammation or fat deposition was not seen as a result of processes such as hepatitis viral infection or NASH. On histology in the present case, hepatic sinusoidal fibrosis extending from centrilobular areas toward the portal tract without inflammation were observed. Schwarz et al. discussed that hepatic fibrosis after the Fontan procedure was a mixed disease that affects both the portal and centrilobular areas in liver biopsy and autopsy specimens ([@B6],[@B7]). Sinusoidal fibrosis is believed to result from an increase in central venous pressure transmitted to hepatic cells that surround the central veins, because the extent of cirrhosis is strongly correlated with elevated hepatic venous pressures and a low cardiac index in patients after undergoing the Fontan procedure ([@B8]). After Fontan palliation, a significant liver disease can result in central venous congestion and hypoxia resulting from a low cardiac output, however, little is known regarding fibrogenic mechanisms independent of the inflammation-mediated pathway in congestive liver disease (CLD). In CLD, mechanotransduction associated with stretching and compression of hepatic stellate cells may be a potent inducer of hepatic fibrosis ([@B9],[@B10]). Using a newly characterized murine CLD model, sinusoidal thrombosis and mechanical stretching of adjacent hepatic stellate cells caused by sinusoidal dilatation was shown to induce the release of fibronectin by hepatic stellate cells, and both fibrin and stretching stimulated fibronectin fibril assembly through a β1-integrin and actin-dependent mechanism ([@B11]).

In addition, hepatic complications after the Fontan procedure are associated with the duration of follow-up ([@B8],[@B12]). Progression to cirrhosis may even be observed within 10 years after the initial Fontan procedure ([@B13]). In 34 patients with a median follow-up of 11.5 years after the Fontan procedure, 30% experienced abnormal transaminases, 61% abnormal γ-GTP, 32% abnormal bilirubin, and 58% coagulopathy ([@B14]). As compared to a duration of 0-5 years, the odds ratio of hepatic complications was 4.4 for a post-Fontan duration of 11-15 years and 9.0 for a duration of 16-20 years, respectively ([@B12]).

Liver cirrhosis is a potential prerequisite for HCC, however, the prevalence and progression of cirrhotic changes in the Fontan population have not been clearly identified. Non-invasive diagnostic tools for hepatic fibrosis are needed, because a liver biopsy, the golden standard for diagnosing liver cirrhosis, is difficult to perform in Fontan patients due to prophylactic anticoagulation. Similar to the present case, a radiological assessment of liver fibrosis using various methods such as US, CT, or MRI may be useful.

There are several reports of HCC in patients with CLD following the Fontan procedure.

As shown in [Table 2](#t002){ref-type="table"}, a recent PubMed search identified 12 cases of HCCs among published reports. The publications described the use of surgical resection, transcatheter arterial chemoembolization, radioembolization, local ablation, or sorafenib therapy ([@B15]-[@B22]). In previous reports, two patients were treated with surgical resection ([@B20],[@B21]). For early stage HCC, surgical resection provides curative treatment with a long-time survival, however, hepatectomy is rarely performed following the Fontan procedure because it is difficult to detect early stage HCCs. Although the present patient did not receive periodic surveillance for HCC, such as US and AFP, it is fortunate that early stage HCC was incidentally detected. HCC detected after the onset of symptoms has a poor prognosis (5-year survival rate of 0-10%). In contrast, early stage HCCs detected by surveillance can be cured with both surgical resection and liver transplantation (5-year disease-free survival rate \>50%) ([@B23]).

###### 

Reported Cases of Hepatocellular Carcinoma after Fontan Procedure.

  Reference   No. of cases   Age(y)   Sex   AFP (ng/mL)   Size (mm)   Treatment            Outcome
  ----------- -------------- -------- ----- ------------- ----------- -------------------- ---------
  15          1              24       M     ND            40          ND                   Died
  16          2              27       F     162.7         22.1        Systemic chemo       Died
                             28       F     788           40          Sorafenib            Died
  17          4              32       F     700           40          TACE                 Alive
                             24       M     5,000         ND          ND                   Died
                             33       M     630           ND          Radioembolization    Died
                             42       F     106           ND          TACE                 Alive
  18          1              51       M     ND            10          Local ablation       Alive
  19          1              19       F     ND            ND          Sorafenib            Died
  20          1              23       F     ND            148         Surgical resection   Alive
  21          1              32       M     13            40          Surgical resection   Alive
  22          1              15       M     2             ND          TAE                  Died
  Our case    1              29       F     117.1         15          Surgical resection   Alive

F: female, M: male, ND: not described, TACE: transarterial chemoembolization, TAE: transarterial embolization

Thus, surveillance for HCC may be necessary in patients with CLD who undergo the Fontan procedure because cirrhosis is a high-risk factor for HCC. However, the screening interval for liver disease after the Fontan procedure has not yet been established. Surveillance is based on an ultrasound examination, and the recommended screening interval is 6 months according to the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of HCC ([@B24]). In addition, the AFP level in the present case was high. In Japan ([@B25]), all patients with high-risk risk factors for HCC are advised to undergo periodic surveillance with US and laboratory work ups, including AFP and protein induced by vitamin K absence or antagonists-II (PIVKA-II), every 6 months. However, similar to the present case, PIVKA-II is not useful in most patients after the Fontan procedure because prophylactic antiplatelet with anticoagulation therapies, such as warfarin administration, are necessary to prevent thromboembolic events, which are one of the major causes of morbidity and mortality ([@B26]). Following the Fontan procedure, patients face a risk of HCC and require a lifelong follow-up with not only a pediatric cardiologist, but also a hepatologist experienced in the care of patients with liver cirrhosis.

We herein described a patient with HCC who was able to safely undergo liver resection following the Fontan procedure under a preserved cardiac and hepatic function.
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